RPRX — Royalty Pharma Income Statement
0.000.00%
Last trade - 00:00
- $16.45bn
- $24.78bn
- $2.35bn
- 80
- 39
- 56
- 59
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 1,814 | 2,122 | 2,289 | 2,237 | 2,355 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | -809 | 557 | 859 | 1,930 | 862 |
Operating Profit | 2,623 | 1,565 | 1,431 | 307 | 1,492 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 2,461 | 1,702 | 1,241 | 230 | 1,700 |
Provision for Income Taxes | |||||
Net Income After Taxes | 2,461 | 1,702 | 1,241 | 230 | 1,700 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 2,349 | 975 | 620 | 42.8 | 1,135 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | 2,349 | 495 | 620 | 42.8 | 1,528 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 3.94 | 1.75 | 1.49 | 1.5 | 2.53 |
Dividends per Share |